echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Lancet Haematol: Iberdomide plus dexamethasone for relapsed/refractory multiple myeloma

    Lancet Haematol: Iberdomide plus dexamethasone for relapsed/refractory multiple myeloma

    • Last Update: 2022-10-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Iberdomide is a novel cerebellar E3 ligase modulator that has a stronger killing of tumor cells and immunostimulatory effects


    This multi-cohort, open-label Phase 1/2 trial in Europe, Canada, and the United States enrolled multiple myeloma patients aged 18 years and older who


    Between 5 December 2016 and 16 December 2020, the condition of 460 patients was evaluated, of whom 197 were enrolled in the group and received Iberdomide+ dexamethasone (90 in dose-increasing cohorts and 107 in dose-extended cohorts).


    As of 2 June 2021, the dose-increasing cohort and the dose-extended cohort were followed up for a median of 5.


    The most common adverse reactions of grade 3 and above were neutropenia (45%), anemia (28%), infection (27%), and thrombocytopenia (22%)


    Overall, Iberdomide plus dexamethasone is generally safe in a large number of patients with multiple myeloma who have been pretreated and exhibit meaningful clinical activity that merits further evaluation


     

    Original Source:

    Sagar Lonial, et al.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.